Physician profile
Richard P Valuck
NPI 1366444549
$4,371.41
in general payments reported to CMS, 2019-2025
33 companies · $768 in 2025
The $768 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $11.83 · 2021: $269 · 2022: $1,220 · 2023: $601 · 2024: $942 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,311.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $770.17 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $407.62 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $361.38 | 2022-2025 | Watchman Access System |
| Amgen INC. | $344.59 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $225.86 | 2019-2023 | Brilinta |
| Pfizer INC. | $224.71 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.12 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $200.55 | 2022-2025 | |
| Scpharmaceuticals INC. | $182.27 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $179.34 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $175.98 | 2019-2024 | Xarelto |
| Esperion Therapeutics, INC. | $141.92 | 2021-2025 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $141.80 | 2019-2025 | Evkeeza, Praluent |
| Abbott Laboratories | $123.41 | 2021-2024 | Jot Dx |
| Actelion Pharmaceuticals US, INC. | $116.79 | 2019-2024 | Opsumit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $106.50 | 2019-2024 | |
| Gilead Sciences, INC. | $64.25 | 2019 | |
| Lundbeck LLC | $61.42 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $49.93 | 2024 | Arcalyst |
| Amryt Pharma Holdings LTD | $37.88 | 2022 | |
| Novo Nordisk INC | $32.06 | 2019-2021 | |
| Abiomed | $24.22 | 2024 | Impella |
| Phathom Pharmaceuticals, INC. | $22.90 | 2025 | Voquezna |
| Lemaitre Vascular, INC. | $21.75 | 2023 | Tyke, Patch, Pledget and Intracardiac |
| Atricure, INC. | $19.09 | 2025 | Atriclip Laa Exclusion System, Synergy Ablation System |
| Ge Healthcare | $18.67 | 2019 | |
| Vital Connect, INC | $18.05 | 2024 | Vitalpatch Rtm |
| Sanofi Pasteur INC. | $17.60 | 2022 | |
| Cvrx, INC. | $16.54 | 2022 | |
| Vifor Pharma, INC. | $15.83 | 2019 | |
| Zimmer Biomet Holdings, INC. | $14.68 | 2025 | Sternalock |
| Chiesi USA, INC. | $14.19 | 2022 | |
| Daiichi Sankyo INC. | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Valuck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.